Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM10560A in Adult Growth Hormone Deficiency
NCT01822340Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2011
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efpegsomatropin in growth hormone deficiency (GHD), sponsored by Hanmi Pharmaceutical. Started Oct 2011; status: completed.
02
Drugs
efpegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT01822340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822340.